首页> 外文期刊>International Journal of Molecular Sciences >The Important Molecular Markers on Chromosome 17 and Their Clinical Impact in Breast Cancer
【24h】

The Important Molecular Markers on Chromosome 17 and Their Clinical Impact in Breast Cancer

机译:17号染色​​体的重要分子标志物及其在乳腺癌中的临床影响

获取原文
           

摘要

Abnormalities of chromosome 17 are important molecular genetic events in human breast cancers. Several famous oncogenes (HER2, TOP2A and TAU), tumor suppressor genes (p53, BRCA1 and HIC-1) or DNA double-strand break repair gene (RDM1) are located on chromosome 17. We searched the literature on HER2, TOP2A, TAU, RDM1, p53, BRCA1 and HIC-1 on the Pubmed database. The association of genes with chromosome 17, biological functions and potential significance are reviewed. In breast cancer, the polysomy 17 (three or more) is the predominant numerical aberration. HER2 amplification is widely utilized as molecular markers for trastuzumab target treatment. Amplified TOP2A, TAU and RDM1 genes are related to a significant response to anthracycline-based chemotherapy, taxane or cisplatin, respectively. In contrast, p53, BRCA1 and HIC-1 are important tumor suppressor genes related to breast carcinogenesis. This review focused on several crucial molecular markers residing on chromosome 17. The authors consider the somatic aberrations of chromosome 17 and associated genes in breast cancer.
机译:17号染色​​体异常是人类乳腺癌中重要的分子遗传事件。几个著名的癌基因(HER2,TOP2A和TAU),抑癌基因(p53,BRCA1和HIC-1)或DNA双链断裂修复基因(RDM1)位于第17号染色​​体上。我们在HER2,TOP2A,TAU上搜索了文献。 ,Pubmed数据库上的RDM1,p53,BRCA1和HIC-1。审查了基因与17号染色​​体的关联,生物学功能和潜在意义。在乳腺癌中,多态性17(三个或更多)是主要的数值像差。 HER2扩增被广泛用作曲妥珠单抗靶标治疗的分子标记。扩增的TOP2A,TAU和RDM1基因分别与基于蒽环类的化学疗法,紫杉烷或顺铂的显着反应有关。相反,p53,BRCA1和HIC-1是与乳腺癌致癌相关的重要肿瘤抑制基因。这项审查集中在染色体17上的几个关键的分子标记。作者考虑了乳腺癌中染色体17和相关基因的体细胞畸变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号